Amarin Corp. Plc (AMRN)
13.63
-0.08
(-0.58%)
USD |
NASDAQ |
Sep 04, 16:00
13.58
-0.05
(-0.37%)
After-Hours: 20:00
Amarin Research and Development Expense (Quarterly) : 4.144M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.144M |
| March 31, 2026 | 4.020M |
| December 31, 2025 | 4.662M |
| September 30, 2025 | 3.320M |
| June 30, 2025 | 4.238M |
| March 31, 2025 | 4.600M |
| December 31, 2024 | 5.199M |
| September 30, 2024 | 3.826M |
| June 30, 2024 | 3.990M |
| March 31, 2024 | 4.833M |
| December 31, 2023 | 5.101M |
| September 30, 2023 | 4.346M |
| June 30, 2023 | 4.926M |
| March 31, 2023 | 4.961M |
| December 31, 2022 | 4.512M |
| September 30, 2022 | 4.948M |
| June 30, 2022 | 8.500M |
| March 31, 2022 | 9.218M |
| December 31, 2021 | 4.978M |
| September 30, 2021 | 7.008M |
| June 30, 2021 | 5.561M |
| March 31, 2021 | 8.897M |
| December 31, 2020 | 8.066M |
| September 30, 2020 | 9.867M |
| June 30, 2020 | 9.482M |
| Date | Value |
|---|---|
| March 31, 2020 | 9.778M |
| December 31, 2019 | 10.92M |
| September 30, 2019 | 8.660M |
| June 30, 2019 | 6.934M |
| March 31, 2019 | 7.150M |
| December 31, 2018 | 11.64M |
| September 30, 2018 | 13.93M |
| June 30, 2018 | 17.77M |
| March 31, 2018 | 11.67M |
| December 31, 2017 | 11.94M |
| September 30, 2017 | 10.58M |
| June 30, 2017 | 13.79M |
| March 31, 2017 | 10.18M |
| December 31, 2016 | 9.109M |
| September 30, 2016 | 12.25M |
| June 30, 2016 | 11.84M |
| March 31, 2016 | 12.71M |
| December 31, 2015 | 12.46M |
| September 30, 2015 | 12.83M |
| June 30, 2015 | 11.57M |
| March 31, 2015 | 11.62M |
| December 31, 2014 | 12.17M |
| September 30, 2014 | 14.32M |
| June 30, 2014 | 12.02M |
| March 31, 2014 | 12.01M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Neurocrine Biosciences, Inc. | 326.70M |
| Alkermes Plc | 111.12M |
| DBV Technologies SA | 28.96M |
| Cellectis SA | 20.89M |
| Akari Therapeutics Plc | 2.081M |